ClinicaliQ Trial Snapshot
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Active Not Recruiting • Phase II / Phase III • Gastroenterology • NCT04033445.
- Guselkumab was tested for treating moderate to severe ulcerative colitis, assessing whether it works and is safe.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC). Conditions: Ulcerative Colitis Interventions: Placebo, Guselkumab Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 1064 participants